Reducing immune tolerance induced by PD-L1
AssigneeInnovative Cellular Therapeutics, Inc.
InventorZhao Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).
Claims20
A pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the human T cells of the population include human T cells that comprise an isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR), wherein the modified PD-1 comprises amino acid sequence SEQ ID NO:
- 9, SEQ ID NO:
- 13, SEQ ID NO:
- 12, or SEQ ID NO:
- 14, wherein the modified PD-1 and the CAR are expressed as gene products that are separate polypeptides;
- and wherein the modified PD-1 is a dominant negative PD-1.
A pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the human T cells of the population include human T cells that comprise an isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR), wherein the modified PD-1 comprises amino acid sequence SEQ ID NO:
- 9, SEQ ID NO:
- 12, SEQ ID NO:
- 13, or SEQ ID NO:
- 14 and inhibits activities of the wild-type PD-1 on the human T cells induced by PD-L1 of a tumor cell.
Dependencies are inferred from the claim text.